Drug Search Results
More Filters [+]

Tranexamic acid

Alternative Names: tranexamic acid, cyklokapron, transamin, exacyl, lysteda, retavase
Latest Update: 2024-06-13
Latest Update Note: Clinical Trial Update

Product Description

Tranexamic acid is used to treat heavy menstrual bleeding in women. This medicine may be used by teenage females, but is not intended for use before the start of menstruation. Tranexamic acid is an antifibrinolytic agent. It works by blocking the breakdown of blood clots, which prevents bleeding. (Sourced from: https://www.mayoclinic.org/drugs-supplements/tranexamic-acid-oral-route/description/drg-20073517)

Mechanisms of Action: Fibrinolysis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Topical,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Injuries/wounds Unspecified

Known Adverse Events: Migraine Disorders | Abdominal Pain | Back Pain | Headache | Pain Unspecified | Anemia | Muscle Cramp | Musculoskeletal Pain

Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tranexamic acid

Countries in Clinic: Australia, Belgium, China, Croatia, Denmark, Germany, Hungary, New Zealand, Nigeria, Pakistan, Qatar, Romania, Spain, Tanzania, United States, Unknown Location, Zambia

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: Acute Respiratory Distress Syndrome|Anaphylaxis|Anemia|Blood Coagulation Disorders|Brain Death|Brain Hemorrhage, Traumatic|Cardiac Arrest|Central Cord Syndrome|Coma|Heart Failure, Acute|Heart Failure, Chronic|Heart Failure, Systolic|Hematoma, Subdural, Chronic|Hemostatic Disorders|Hip Fracture|Hypotension|Injuries/wounds Unspecified|Melanoma|Pregnancy Outcomes|Ranula|Respiratory Insufficiency|Sarcoma|Sepsis|Severe Acute Respiratory Syndrome|Total Knee Arthroplasty

Phase 2: Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TIC-TOC

P3

Not yet recruiting

Brain Hemorrhage, Traumatic

2030-03-31

PRIME

P3

Recruiting

Melanoma

2026-09-01

STOP-MSU

P2

Active, not recruiting

Stroke

2026-01-27

TATRA

P3

Not yet recruiting

Anemia

2025-11-30

Recent News Events